郑州近视眼手术多少钱(郑州参军近视矫正) (今日更新中)

WASHINGTON, Nov. 21 (Xinhua) -- The use of acupuncture for children is common and acupuncture is generally safe for children when performed by "appropriately trained practitioners," Canadian researchers reported Monday in online journal Pediatrics.Researchers at the University of Alberta looked at data from 37 studies of needle acupuncture, spanning 60 years, on children from birth to age 17, and assessed the association between needle acupuncture and various levels of adverse events in children. They found that of 279 adverse events identified, 253 were mild, one was moderate and 25 were serious.Serious side effects included bleeding, infections, and heart and lung problems. One child may have contracted HIV. But the researchers said the serious side effects were related to substandard conditions from the care provider, rather than acupuncture's technique itself. They concluded that in trained hands, pediatric acupuncture is safe.Acupuncture has been around for thousands of years, and traditional Chinese theory suggests needle placement helps balance the body's energy flow, called "qi". Acupuncture is sometimes used to treat headaches, migraines, back and joint pains, cramps, and chemotherapy-induced nausea. Estimates show 150,000 U.S. children undergo acupuncture each year.

WASHINGTON, Oct. 3 (Xinhua) -- Researchers at St. Michael's Hospital in Canada have discovered a new function for an enzyme that may protect against organ injury and death from anemia, according to a study appearing Monday in the U.S. journal of the Proceeding of the National Academy of Sciences.Researchers found that when people have anemia, neuronal nitric oxide synthase (nNOS) -- an enzyme in nerve cells that produces nitric oxide, an important signaling molecule in the body -- increases the body's ability to respond, adapt to low oxygen levels and makes the body more efficient in delivering oxygen to tissues. They also found that levels of nNOS in the brain increased in anemic mice, and that the mice without this enzyme die earlier, and with higher hemoglobin levels."Identifying this mechanism may lead to new therapies and approaches to improving outcomes for anemic patients," said Dr. Greg Hare, a researcher at the Li Ka Shing Knowledge Institute of the hospital and one of the lead investigators of the study.Anemia occurs when blood has a lower than normal number of red blood cells or hemoglobin -- an iron-rich protein that carries oxygen from the lungs and heart to the rest of the body. Cells need oxygen to survive and to produce energy for all bodily functions. The condition has many different causes including infection (malaria, HIV, parasites), nutritional deficiencies (iron, folate, B12), genetic mutations, pregnancy, trauma and surgical blood loss."This research will help us identify when an anemic patient is at greatest risk for injury and death when undergoing surgery," said Hare. "Research is underway to test these findings in humans."

BEIJING, Jan. 10 (Xinhuanet) -- Conflicts among hundreds of scalpers raring to stock up on the new iPhone 4S are casting a shadow over the gadget's launch on the Chinese mainland on Friday.Over the weekend, scalpers from two groups bickered and shoved each other when standing in line to purchase iPhone 4 at Apple's Sanlitun store, said witnesses.Workers from two Apple stores in Beijing told China Daily the stores have not started online bookings for the iPhone 4S so far."More than 1,000 of us have gathered to buy all the available iPhone 4 this morning," said a scalper hawking the phone outside the Sanlitun store on Sunday."We'll come again on Friday for iPhone 4S. You'll have no hope of getting an iPhone 4 or 4S from the store, but only from us."The scalpers are asking 4,450 yuan (705 U.S. dollars) for an 8-gigabyte iPhone 4, and 5,450 yuan for a smuggled iPhone 4S. Apple sells an 8-gigabyte iPhone 4 on the mainland for 3,988 yuan.An Apple employee at the Sanlitun store who declined to give her name told China Daily on Monday that the store was aware the scalpers may be planning to besiege the iPhone 4S launch, and the store has prepared for that.Calls to the public relations office of Apple China went straight to voice mail.Police of the Sanlitun police station refused China Daily's interview request.An officer of the property management company of the Sanlitun Village shopping mall, where the store is located, said on Sunday they had not been informed about the weekend fracas outside of the Apple store.But on Monday afternoon, staff members of the company dispersed the scalpers by sealing off part of the store's entrance.Workers at the Sanlitun store and property management staff confirmed two groups of scalpers fought on Saturday afternoon and Sunday when jumping the line or stopping each other to pay to get an iPhone 4.Since October 2010, Apple has ceased direct sales of iPhone 4 at its retail outlets in Beijing and Shanghai and is only accepting online orders or reservations and schedules pick-up at stores to curb rampant scalping.But the registration system for reserve and pick-up has become "momentarily unavailable because of heavy traffic volume" in recent days, said Apple's website.A scalper in his 30s outside the Sanlitun store boasted they had "hacked" Apple's reservation page. He described himself an "unofficial salesman" of Apple.Defending the actions of scalpers that lead to consumers having to pay more, he said "it's not our fault but Apple's, because they put too few products in the mainland market."This is not the first time scalpers have targeted Apple products.Two men and two women suffered minor injuries outside the Sanlitun store during a clash between a worker and angry customers as Apple fans waited to buy iPhone 4 and the newly released iPad 2 in May 2011.According to reports, the incident started when a worker confronted an alleged scalper for jumping the line. This led to a verbal conflict in which the alleged scalper was thrown against the corner of an outside wall, causing injuries to his face and wrist

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

BEIJING, Dec. 4 (Xinhua) -- Acclaimed orthopaedic surgeons and experts attending a major conference in Beijing have agreed to build up a platform for international cooperation aiming at jointly coping with medical and social challenges.At the Sixth International Congress of the Chinese Orthopaedic Association (COA) that concluded on Sunday, presidents of more than 80 national and international orthopaedic societies signed a declaration which seeks a model for both developing and developed countries to help reduce medical costs in the aftermath of the global financial crisis.With an aging global population, rapidly rising medical costs have become a heavy financial burden for governments worldwide. Medical insurance cost control has become a hot topic around the world.Bone and joint diseases, infections due to traffic accident traumas and other diseases causing high disability rates have affected millions of people worldwide."One of the objectives of the COA international conference is to provide a platform for medical experts around the world to discuss not only clinical techniques but also medical and social problems," said Professor Wang Yan, chairman of the COA.To fully leverage existing professional knowledge and resources, presidents of orthopaedic organizations attending the conference adopted and released the Beijing Declaration which calls for a platform to enhance global and national collaboration and partnerships among the professions, industries and related patient organizations and disciplines.The declaration also stresses maximizing Internet-based learning and encouraging international exchanges."Worldwide, I have one lament, that we've spent so much money on medical research, but very little on orthopaedics. Most governments are more anxious to fund cancer or infectious diseases," said Professor Michael Huggness, president of the North American Spine Society."We think we're a bit handicapped by not having the money to pursue the research. As we get more sophisticated in our treatment, the price does go up. My expectation is that in another five to 10 years, we'll begin to apply some molecular techniques to assist us in healing. Maybe the price will come down when our knowledge base increases. But I think we'll just have to wait for a bit more research and a bit more basic science.""We definitely will... look into this issue of how we can have a suitably assigned budget from the government for orthopaedic care," said Professor K.M. Chan, from the Prince of Wales Hospital in Hong Kong."At the same time, we use evidence-based medicine to contain the medical cost in orthopaedics with very stringent monitors from the professions. That involves good-practice models, quality insurance and patient safety. With all these, we expect that the profession will be heading forward to join hands with the government to contain the cost."More than 15,000 surgeons, researchers and business representatives from China and abroad are attending the four-day annual conference to share the latest theories and techniques for curing musculoskeletal diseases as well as related social topics.Founded in 1980, the COA now has more than 30,000 registered members and is the largest sub-society of doctors under the Chinese Medical Association. The conference is the largest medical academic event in China.

来源：资阳报